The 14-3-3 protein in multiple sclerosis: a marker of disease severity

被引:47
作者
Colucci, M
Roccatagliata, L
Capello, E
Narciso, E
Latronico, N
Tabaton, M
Mancardi, Gl
机构
[1] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy
[2] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy
[3] Univ Brescia, Ist Anestesia & Rianimaz, I-25125 Brescia, Italy
关键词
14-3-3; protein; cerebrospinal fluid; multiple sclerosis; tau protein;
D O I
10.1191/1352458504MS1089OA
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Context: In multiple sclerosis ( MS) axonal damage is an early event and is probably to be considered the most relevant cause of permanent and progressive disability. Objectives: To investigate the value of the increase of 14-3-3 and tau proteins in the cerebrospinal fluid (CSF) as peripheral markers of axonal pathology and predictors of disease evolution. Patients and methods: In the CSF samples obtained from 63 patients with demyelinating diseases ( DD), including 20 clinically isolated syndromes (CIS) and 43 clinically defined MS, as well as from 56 controls, we analysed the presence of 14-3-3 reactivity by immunoblot analysis along with the concentration of tau protein by sandwich ELISA. Results: The percentage of DD subjects showing a positive 14-3-3 protein CSF reactivity (38%) was significantly higher than the one previously detected, and was correlated in the MS patients with a more severe clinical phenotype in terms of degree of disability and rate of disease progression, during a 10-month mean clinical follow-up. On the contrary, the levels of the CSF-tau protein were highly variable in DD and control subjects, and the mean CSF-tau concentration was similar in both groups. Conclusions: The immunoblot analysis of 14-3-3 protein in the CSF could be a useful marker to identify a subgroup of DD patients with high risk of developing severe disability.
引用
收藏
页码:477 / 481
页数:5
相关论文
共 24 条
[1]   Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis [J].
Barkhof, F ;
Filippi, M ;
Miller, DH ;
Scheltens, P ;
Campi, A ;
Polman, CH ;
Comi, G ;
Ader, HJ ;
Losseff, N ;
Valk, J .
BRAIN, 1997, 120 :2059-2069
[2]   A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [J].
Brex, PA ;
Ciccarelli, O ;
O'Riordan, JI ;
Sailer, M ;
Thompson, AJ ;
Miller, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :158-164
[3]   CSF detection of the 14-3-3 protein in unselected patients with dementia [J].
Burkhard, PR ;
Sanchez, JC ;
Landis, T ;
Hochstrasser, DF .
NEUROLOGY, 2001, 56 (11) :1528-1533
[4]   14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis [J].
de Seze, J ;
Peoc'h, K ;
Ferriby, D ;
Stojkovic, T ;
Laplanche, JL ;
Vermersch, P .
JOURNAL OF NEUROLOGY, 2002, 249 (05) :626-627
[5]   Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis - Results of a longitudinal magnetic resonance spectroscopy study [J].
De Stefano, N ;
Matthews, PM ;
Fu, LQ ;
Narayanan, S ;
Stanley, J ;
Francis, GS ;
Antel, JP ;
Arnold, DL .
BRAIN, 1998, 121 :1469-1477
[6]   Axonal damage in acute multiple sclerosis lesions [J].
Ferguson, B ;
Matyszak, MK ;
Esiri, MM ;
Perry, VH .
BRAIN, 1997, 120 :393-399
[7]  
Frankel A, 1996, CLIN CANCER RES, V2, P1307
[8]   The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies [J].
Hsich, G ;
Kinney, K ;
Gibbs, CJ ;
Lee, KH ;
Harrington, MG .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (13) :924-930
[9]   14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis [J].
Irani, DN ;
Kerr, DA .
LANCET, 2000, 355 (9207) :901-901
[10]   Increased cerebrospinal fluid tau protein in multiple sclerosis [J].
Kapaki, E ;
Paraskevas, GP ;
Michalopoulou, M ;
Kilidireas, K .
EUROPEAN NEUROLOGY, 2000, 43 (04) :228-232